HEXO Relative Valuation - Hexo Corp

Watchlist Manager

Watchlist

Price: 0.88 CAD 1.15% Market Closed

Market Cap: CA$38.7m

Relative Value

There is not enough data to reliably calculate the relative value of HEXO.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

What is Relative Valuation?

How is Relative Value calculated?

HEXO Relative Value

Base Case

Worst Case

Base Case

Best Case

Valuation Multiples

View Details

Multiples Across Competitors

All Multiples

P/S

P/E

EV/EBITDA

EV/EBIT

Forward Multiples

			Market Cap	P/S	P/E	EV/EBITDA	EV/EBIT
CA		Hexo Corp TSX:HEXO	38.7m CAD	0.3	-0.1	-1.9	-1.5
US		Eli Lilly and Co NYSE:LLY	964.4B USD	14.8	46.7	31.5	33.5
US		Johnson & Johnson NYSE:JNJ	572.6B USD	6.1	21.4	14.9	18.2
CH		Roche Holding AG SIX:ROG	284.3B CHF	4.6	30.3	12.8	14.9
US		Merck & Co Inc NYSE:MRK	297.7B USD	4.6	16.3	10.2	11.9
CH		Novartis AG SIX:NOVN	228.8B CHF	5.2	21.1	13	16.7
UK		AstraZeneca PLC LSE:AZN	217.7B GBP	5.2	32.1	15.3	22.4
IE	E	Endo International PLC LSE:0Y5F	218B USD	94	-74.6	333.1	835.4
DK		Novo Nordisk A/S CSE:NOVO B	1.3T DKK	4.2	12.7	9.3	10.9
US		Pfizer Inc NYSE:PFE	151.1B USD	2.4	19.4	7.3	9.7
US		Bristol-Myers Squibb Co NYSE:BMY	120.9B USD	2.5	20	7.1	9.3

				Revenue Growth	P/S to Growth
CA		Hexo Corp TSX:HEXO	Average P/S: 13.1 0.3	-9%	N/A
US		Eli Lilly and Co NYSE:LLY	14.8	15%	1
US		Johnson & Johnson NYSE:JNJ	6.1	6%	1
CH		Roche Holding AG SIX:ROG	4.6	3%	1.5
US		Merck & Co Inc NYSE:MRK	4.6	5%	0.9
CH		Novartis AG SIX:NOVN	5.2	4%	1.3
UK		AstraZeneca PLC LSE:AZN	5.2	8%	0.6
IE	E	Endo International PLC LSE:0Y5F	94	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	4.2	7%	0.6
US		Pfizer Inc NYSE:PFE	2.4	-3%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	2.5	-3%	N/A

				Earnings Growth	PEG
CA		Hexo Corp TSX:HEXO	Average P/E: 24.4 Negative Multiple: -0.1	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	46.7	28%	1.7
US		Johnson & Johnson NYSE:JNJ	21.4	6%	3.6
CH		Roche Holding AG SIX:ROG	30.3	29%	1
US		Merck & Co Inc NYSE:MRK	16.3	14%	1.2
CH		Novartis AG SIX:NOVN	21.1	15%	1.4
UK		AstraZeneca PLC LSE:AZN	32.1	38%	0.8
IE	E	Endo International PLC LSE:0Y5F	Negative Multiple: -74.6	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	12.7	7%	1.8
US		Pfizer Inc NYSE:PFE	19.4	26%	0.7
US		Bristol-Myers Squibb Co NYSE:BMY	20	N/A	N/A

				EBITDA Growth	EV/EBITDA to Growth
CA		Hexo Corp TSX:HEXO	Average EV/EBITDA: 45.4 Negative Multiple: -1.9	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	31.5	18%	1.8
US		Johnson & Johnson NYSE:JNJ	14.9	2%	7.4
CH		Roche Holding AG SIX:ROG	12.8	5%	2.6
US		Merck & Co Inc NYSE:MRK	10.2	7%	1.5
CH		Novartis AG SIX:NOVN	13	9%	1.4
UK		AstraZeneca PLC LSE:AZN	15.3	10%	1.5
IE	E	Endo International PLC LSE:0Y5F	333.1	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	9.3	7%	1.3
US		Pfizer Inc NYSE:PFE	7.3	-4%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	7.1	-9%	N/A

				EBIT Growth	EV/EBIT to Growth
CA		Hexo Corp TSX:HEXO	Average EV/EBIT: 98.3 Negative Multiple: -1.5	N/A	N/A
US		Eli Lilly and Co NYSE:LLY	33.5	17%	2
US		Johnson & Johnson NYSE:JNJ	18.2	6%	3
CH		Roche Holding AG SIX:ROG	14.9	6%	2.5
US		Merck & Co Inc NYSE:MRK	11.9	6%	2
CH		Novartis AG SIX:NOVN	16.7	12%	1.4
UK		AstraZeneca PLC LSE:AZN	22.4	23%	1
IE	E	Endo International PLC LSE:0Y5F	835.4	N/A	N/A
DK		Novo Nordisk A/S CSE:NOVO B	10.9	8%	1.4
US		Pfizer Inc NYSE:PFE	9.7	-1%	N/A
US		Bristol-Myers Squibb Co NYSE:BMY	9.3	10%	0.9

Hexo Corp
TSX:HEXO

Relative Value

Valuation Multiples

Multiples Across Competitors

HEXO Competitors Multiples
Hexo Corp Competitors

See Also

Company

Help

Tools

Stocks

Hexo Corp TSX:HEXO

Relative Value

Valuation Multiples

Multiples Across Competitors

HEXO Competitors Multiples Hexo Corp Competitors

See Also

Company

Help

Tools

Stocks

Hexo Corp
TSX:HEXO

HEXO Competitors Multiples
Hexo Corp Competitors